What are the indications for pembrolizumab (Keytruda) in early-stage triple‑negative breast cancer?

Pembrolizumab Indications in Early-Stage Triple-Negative Breast Cancer

Pembrolizumab is indicated for patients with high-risk early-stage TNBC (stage II-III, defined as cT2-4 N0 or any N-positive disease) as neoadjuvant therapy combined with chemotherapy, followed by adjuvant pembrolizumab after surgery, regardless of pathological complete response status.

Primary Indication: Stage II-III TNBC

The FDA-approved indication and guideline-recommended use is clear 1:

• Stage II-III TNBC (cT2-4 N0 or any node-positive disease)
• Treatment consists of neoadjuvant pembrolizumab combined with chemotherapy, then continued as adjuvant monotherapy after surgery
• No PD-L1 testing required for early-stage disease (unlike metastatic TNBC where CPS ≥10 is required)

Treatment Regimen

Preferred Regimen (Category 1)

The KEYNOTE-522 protocol is the standard 2, 3:

Neoadjuvant Phase:

• Pembrolizumab 200 mg every 3 weeks + carboplatin + paclitaxel (4 cycles)
• Followed by pembrolizumab 200 mg every 3 weeks + doxorubicin/cyclophosphamide or epirubicin/cyclophosphamide (4 cycles)

Adjuvant Phase:

• Pembrolizumab 200 mg every 3 weeks for 9 cycles (regardless of pCR status) 2

This regimen demonstrated significant improvements in overall survival (86.6% vs 81.7% at 60 months, P=0.002) and event-free survival (84.5% vs 76.8% at 36 months) 4, 5.

Alternative Regimen (Useful in Certain Circumstances)

Anthracycline-free option 3:

• Docetaxel/carboplatin/pembrolizumab (6 cycles neoadjuvant only)
• Consider for patients with contraindications to anthracyclines or those seeking to avoid anthracycline-related risks
• Important caveat: Less effective in node-positive disease compared to the standard KEYNOTE-522 regimen (pCR 45% vs 65% in node-positive patients)
• Should NOT routinely substitute for KEYNOTE-522 regimen

Stage-Specific Considerations

Stage I Disease (cT1c N0)

• Pembrolizumab is not routinely indicated for very low-risk disease (pT1a pN0) 2
• For cT1c N0 disease, neoadjuvant treatment is preferred, and pembrolizumab may be considered 2
• The anthracycline-free regimen showed better results in node-negative disease (pCR 65%) 3

Stage II-III Disease

• Neoadjuvant approach is strongly preferred over adjuvant-only treatment 2
• Pembrolizumab should be given throughout neoadjuvant and adjuvant phases
• Critical: Pembrolizumab should NOT be given solely in the adjuvant setting without prior neoadjuvant ICI treatment 2

Important Contraindications and Monitoring

When NOT to Use Pembrolizumab

• Patients with risk factors for excessive ICI-associated immune toxicity 2
• Very low-risk disease (pT1a pN0) 2
• Special histological subtypes (secretory or adenoid cystic carcinomas) that have excellent prognosis with chemotherapy alone 2

Mandatory Monitoring

Patients must be monitored very closely for immune-related adverse events (irAEs) throughout treatment 2:

• Grade ≥3 irAEs occur in approximately 15-16% of patients 6
• Common irAEs include thyroid dysfunction, pneumonitis, hepatitis, and colitis
• Follow ESMO guidelines for immunotherapy toxicity management 2
• In real-world data, 34% of Japanese patients required unexpected hospitalization during neoadjuvant treatment 6

Special Population: ER-Low (1-9%) HER2-Negative Disease

Treat ER-low/PgR-low (1-9%) HER2-negative tumors similarly to TNBC 2:

• These tumors behave biologically like TNBC
• Show higher response to chemotherapy and reduced efficacy of endocrine therapy
• Real-world data shows excellent pCR rates (87.5%) with pembrolizumab in this population 6

Integration with Other Therapies

If Residual Disease After Neoadjuvant Therapy

For patients with non-pCR after pembrolizumab + chemotherapy:

• Adjuvant capecitabine for 6-8 cycles (for those without gBRCA mutation) 2
• Adjuvant olaparib for 1 year (for gBRCA1/2 mutation carriers with high-risk disease) 2
• The combination of pembrolizumab + capecitabine or pembrolizumab + olaparib may be considered individually 2

Key Sequencing Note

• Do NOT combine olaparib with capecitabine 2
• Optimal sequencing of olaparib and capecitabine is unknown when both are indicated 3

Common Pitfalls to Avoid

1. Do not use pembrolizumab as adjuvant-only therapy without prior neoadjuvant exposure 2
2. Do not skip adjuvant pembrolizumab even if patient achieves pCR—continue for full 9 cycles 2
3. Do not require PD-L1 testing for early-stage TNBC (only required for metastatic disease) 1
4. Do not routinely substitute the anthracycline-free regimen for node-positive disease 3
5. Do not underestimate toxicity—real-world completion rates are lower than trial data (52-65% for full neoadjuvant course) 6